Lyra Therapeutics, Inc.
LYRA
$0.0873
$0.00080.93%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 43.15% | -64.15% | 30.57% | 29.76% | 1,227.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.15% | -64.15% | 30.57% | 29.76% | 1,227.27% |
| Cost of Revenue | -48.13% | -52.28% | 22.83% | 44.79% | -3.04% |
| Gross Profit | 49.23% | 51.73% | -22.48% | -45.30% | 4.11% |
| SG&A Expenses | -17.08% | -21.43% | 12.45% | 13.48% | 263.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.99% | -43.39% | 19.74% | 35.73% | 20.02% |
| Operating Income | 40.73% | 42.72% | -19.41% | -35.87% | -19.06% |
| Income Before Tax | 27.52% | 24.11% | -208.34% | -38.16% | -6.45% |
| Income Tax Expenses | -64.71% | -56.25% | 0.00% | 0.00% | 30.77% |
| Earnings from Continuing Operations | 27.56% | 24.14% | -208.18% | -38.12% | -6.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.56% | 24.14% | -208.18% | -38.12% | -6.47% |
| EBIT | 40.73% | 42.72% | -19.41% | -35.87% | -19.06% |
| EBITDA | 41.34% | 42.74% | -19.48% | -37.34% | -20.38% |
| EPS Basic | 31.95% | 46.80% | -105.62% | 20.51% | 44.94% |
| Normalized Basic EPS | 42.13% | 59.37% | 19.30% | 20.50% | 39.31% |
| EPS Diluted | 31.95% | 46.80% | -105.62% | 20.51% | 44.94% |
| Normalized Diluted EPS | 42.13% | 59.37% | 19.30% | 20.50% | 39.31% |
| Average Basic Shares Outstanding | 6.47% | 42.62% | 49.87% | 73.79% | 93.33% |
| Average Diluted Shares Outstanding | 6.47% | 42.62% | 49.87% | 73.79% | 93.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |